<DOC>
	<DOCNO>NCT02372149</DOCNO>
	<brief_summary>The purpose study determine whether intravenous immunoglobulin ( IVIg ) effective intervention patient diabetes , peripheral neuropathy , demyelination nerve conduction study . All patient receive IVIg placebo 3 month , 3 month washout period .</brief_summary>
	<brief_title>IVIg Demyelination Diabetes Mellitus</brief_title>
	<detailed_description>There knowledge gap regard appropriate method detect treat chronic inflammatory demyelinate polyneuropathy ( CIDP ) , patient co-existent diabetes . In pilot study investigator plan examine overlap diabetic polyneuropathy CIDP treat patient diabetes demyelinate abnormality use IVIg . The investigator enroll diabetes patient broad spectrum demyelinate abnormality . The propose trial explanatory , blind , single-centre , superiority , randomize control cross-over trial . Each patient receive 3 month 10 % intravenous immunoglobulin 3 month placebo ( 0.9 % sodium chloride water ) 3-month washout period . The primary outcome measure mean change ONLS ( Overall Neuropathy Limitation Scale ) , measure disability polyneuropathy ; however secondary outcome measure consider impairment quality life .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Demyelinating Diseases</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Age â‰¥18 year . 2 . Diabetes , per American Diabetes Association Criteria . 3 . Clinical evidence polyneuropathy NCS show 2 separate motor nerve ( median , ulnar , tibial , peroneal ) meet criterion demyelination , define follow : 1 . Conduction velocity &lt; 90 % low limit normal ( LLN ) , distal latency &gt; 110 % upper limit normal ( ULN ) , minimal Fwave latency &gt; 110 % ULN 2 . The change exclusively due median neuropathy wrist , ulnar neuropathy elbow , peroneal neuropathy fibular head . 4 . Clinical suspicion possible demyelinate polyneuropathy ( CIDP ) . 1 . Pregnant patient , childbearing potential use contraception . 2 . Patients &lt; 18 year age . 3 . Presence alternative etiology peripheral neuropathy , : hereditary neuropathy ( Charcot MarieTooth disease ) ; Bvitamin deficiency excessrelated neuropathy ; uremic neuropathy ; neuropathy secondary monoclonal gammopathy ; history cancer chemotherapyrelated neuropathy ; toxin exposure ; alcoholic neuropathy . 4 . Contraindication IVIg , include : history recurrent thrombosis , immunoglobulin A deficiency , severe hypersensitivity reaction IVIg past , renal failure , recurrent deep venous thrombosis , pulmonary embolus , stroke , myocardial infarction . 5 . Presence serious unstable medical condition , may preclude study completion lead inability tolerate IVIg . This may include active heart failure , uncontrolled hypertension , severe anemia , among condition . 6 . Presence concomitant neurological illness , may confound evaluation . 7 . Fails unable provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>